Clinical trial
Diabetes Therapy to Improve BMI and Lung Function in CF
NCT00072904 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT00072904 |
|---|---|
| Title | Diabetes Therapy to Improve BMI and Lung Function in CF |
| Official title | Diabetes Therapy to Improve BMI and Lung Function in CF |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Collaborators | Cystic Fibrosis Foundation Novo Nordisk A/S Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis, Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Insulin Asparte, Repaglinide |
| Enrollment | 108 |
| Start date | Jun 1, 2001 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Nov 14, 2003 |
| Last update posted | Feb 28, 2012 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: